OtherPublishAheadOfPrint
Observer Variation in Interpreting 18F-FDG PET/CT Findings for Lymphoma Staging
Michael S. Hofman, Nigel C. Smeeton, Sheila C. Rankin, Tom Nunan and Michael J. O'Doherty
Journal of Nuclear Medicine September 2009, DOI: https://doi.org/10.2967/jnumed.109.064121
Michael S. Hofman
Nigel C. Smeeton
Sheila C. Rankin
Tom Nunan
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Observer Variation in Interpreting 18F-FDG PET/CT Findings for Lymphoma Staging
Michael S. Hofman, Nigel C. Smeeton, Sheila C. Rankin, Tom Nunan, Michael J. O'Doherty
Journal of Nuclear Medicine Sep 2009, DOI: 10.2967/jnumed.109.064121
Jump to section
Related Articles
Cited By...
- Interobserver Agreement of Interim and End-of-Treatment 18F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials
- In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy
- PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement